Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video hereBOSTON and LONDON – …
Press Release
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer …
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and …
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
BOSTON and LONDON, March 3, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision …
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology …
